This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Genmab Gestion

Gestion contrôle des critères 4/4

Le PDG Genmab's est Jan van de Winkel, nommé en Jun2010, a un mandat de 12.08 ans. La rémunération annuelle totale est DKK 38.10M, composée du salaire de 20.7% et des bonus 79.3%, y compris les actions et options de la société. détient directement 0.94% des actions de la société, d'une valeur de € 214.42M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 3.3 ans et 5.3 ans.

Informations clés

Jan van de Winkel

Directeur général

DKK 38.1m

Rémunération totale

Pourcentage du salaire du PDG	20.7%
Durée du mandat du directeur général	12.1yrs
Propriété du PDG	0.9%
Durée moyenne d'occupation des postes de direction	3.3yrs
Durée moyenne du mandat des membres du conseil d'administration	5.3yrs

Mises à jour récentes de la gestion

Recent updates

Analyse de la rémunération des PDG

Comment la rémunération de Jan van de Winkel a-t-elle évolué par rapport aux bénéfices de Genmab?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Mar 31 2022	n/a	n/a	DKK 2b
Dec 31 2021	DKK 38m	DKK 8m	DKK 3b
Sep 30 2021	n/a	n/a	DKK 3b
Jun 30 2021	n/a	n/a	DKK 3b
Mar 31 2021	n/a	n/a	DKK 6b
Dec 31 2020	DKK 37m	DKK 7m	DKK 5b
Sep 30 2020	n/a	n/a	DKK 6b
Jun 30 2020	n/a	n/a	DKK 6b
Mar 31 2020	n/a	n/a	DKK 2b
Dec 31 2019	DKK 35m	DKK 7m	DKK 2b
Sep 30 2019	n/a	n/a	DKK 2b
Jun 30 2019	n/a	n/a	DKK 1b
Mar 31 2019	n/a	n/a	DKK 1b
Dec 31 2018	DKK 28m	DKK 7m	DKK 1b
Sep 30 2018	n/a	n/a	DKK 1b
Jun 30 2018	n/a	n/a	DKK 1b
Mar 31 2018	n/a	n/a	DKK 1b
Dec 31 2017	DKK 27m	DKK 7m	DKK 1b
Sep 30 2017	n/a	n/a	DKK 1b
Jun 30 2017	n/a	n/a	DKK 1b
Mar 31 2017	n/a	n/a	DKK 1b
Dec 31 2016	DKK 23m	DKK 6m	DKK 1b
Sep 30 2016	n/a	n/a	DKK 735m
Jun 30 2016	n/a	n/a	DKK 686m
Mar 31 2016	n/a	n/a	DKK 535m
Dec 31 2015	DKK 20m	DKK 5m	DKK 764m

Rémunération vs marché: La rémunération totale de Jan ($USD 5.18M ) est dans la moyenne des entreprises de taille similaire sur le marché German ($USD 5.47M ).

Rémunération et revenus: La rémunération de Jan a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.

PDG

Jan van de Winkel (61 yo)

12.1yrs

Titularisation

DKK 38,100,000

Compensation

Dr. Jan G. J. van de Winkel, Ph D., serves as a Member of Advisory board at Thuja Capital Management B.V. Dr. van de Winkel served as a Member of Scientific Advisory Board.He is a Co-Founder of Genmab A/S...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Jan van de Winkel	Co-Founder	12.1yrs	DKK 38.10m	0.94% DKK 214.4m
Anthony Pagano	Executive VP & CFO	2.3yrs	DKK 12.40m	0.0047% DKK 1.1m
Anthony Mancini	Executive VP & COO	2.3yrs	DKK 16.60m	pas de données
Judith Klimovsky	Executive VP & Chief Development Officer	5.4yrs	DKK 19.80m	0.0080% DKK 1.8m
Tahamtan Ahmadi	Executive VP	1.3yrs	DKK 10.90m	0.0037% DKK 841.4k
Mijke Zachariasse	Director of Protein Production & Chemist and Non-Independent Director	no data	DKK 900.00k	0.00014% DKK 31.9k
Rima Nassar	VP, Head of Global Regulatory Affairs – Oncology & Non-Independent Director	no data	DKK 800.00k	0.0016% DKK 362.6k
Peter Ros	Senior Director of Finance & Accounting	no data	pas de données	pas de données
Andrew Carlsen	Senior Director	no data	pas de données	pas de données
Birgitte Stephensen	Executive VP & Chief Legal Officer	12.5yrs	pas de données	pas de données
Christopher Cozic	Executive VP & Chief People Officer	no data	pas de données	pas de données
Rachel Gravesen	Executive Officer	3.3yrs	pas de données	pas de données

3.3yrs

Durée moyenne de l'emploi

52.5yo

Âge moyen

Gestion expérimentée: L'équipe de direction de GE9 est considérée comme expérimentée (ancienneté moyenne 3.3 ans).

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Mijke Zachariasse	Director of Protein Production & Chemist and Non-Independent Director	3.3yrs	DKK 900.00k	0.00014% DKK 31.9k
Rima Nassar	VP, Head of Global Regulatory Affairs – Oncology & Non-Independent Director	2.5yrs	DKK 800.00k	0.0016% DKK 362.6k
Anders Pedersen	Non-Independent Director	18.7yrs	DKK 1.40m	0.017% DKK 3.9m
Deirdre Connelly	Independent Chairman of the Board	5.3yrs	DKK 2.40m	0.0068% DKK 1.6m
Rolf Hoffmann	Independent Director	5.3yrs	DKK 1.40m	0.0045% DKK 1.0m
Pernille Erenbjerg	Independent Deputy Chairman	7.5yrs	DKK 1.80m	0.0066% DKK 1.5m
Paolo Paoletti	Independent Director	7.5yrs	DKK 1.30m	0.00093% DKK 212.1k
Elizabeth O'Farrell	Independent Director	less than a year	pas de données	pas de données

5.3yrs

Durée moyenne de l'emploi

62yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de GE9 sont considérés comme expérimentés (ancienneté moyenne 5.3 ans).

This company listing is no longer active

Genmab Gestion

Gestion contrôle des critères 4/4

Informations clés

Mises à jour récentes de la gestion

Genmab A/S Announces Executive Changes

Genmab A/S Announces Executive Changes

Genmab A/S, Annual General Meeting, Mar 13, 2024

Genmab A/S Elects Elizabeth O’Farrell to the Board of Directors

Genmab A/S Announces Appointments of Birgitte Stephensen to Chief Legal Officer and Chris Cozic to Chief People Officer

High number of new directors

Recent updates

Genmab A/S Receives Second European Commission Approval for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma

Genmab A/S Announces Executive Changes

Genmab A/S Takes Full Control of Acasunlimab Development Program

Genmab A/S Announces That the U.S. Food and Drug Administration Approved Epkinly® (Epcoritamab-Bysp) for the Treatment of Adults with Relapsed or Refractory Follicular Lymphoma After Two or More Lines of Systemic EPKINLY

Genmab A/S Announces New Efficacy and Safety Data from Two Ongoing Phase 1/2 Clinical Trials Evaluating Epcoritamab, A T-Cell Engaging Bispecific Antibody Administered Subcutaneously, in Adult Patients with Certain Types of Follicular Lymphoma

Genmab A/S (CPSE:GMAB) completed the acquisition of ProfoundBio, Inc.

Genmab A/S to Present New and Updated Results from Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies At the 2024 European Hematology Association (Eha) Congress

Pfizer Inc. and Genmab A/S Announce FDA Grants Full Approval for TIVDAK to Treat Recurrent or Metastatic Cervical Cancer

Genmab A/S (CPSE:GMAB) entered into a definitive agreement to acquire ProfoundBio for $1.8 billion.

Genmab A/S (CPSE:GMAB) entered into a definitive agreement to acquire ProfoundBio for $1.8 billion.

Genmab A/S Announces Executive Changes

Genmab A/S and AbbVie Announce U.S. Food and Drug Administration Grants Priority Review for the Supplemental Biologics License Application for Epcoritamab (Epkinly®) for Difficult-To-Treat Relapsed or Refractory Follicular Lymphoma

Genmab A/S and Pfizer, Inc. Announces Validation for Review the Marketing Authorization Application of Tivdak®?

Genmab A/S Announces Decision in Arbitration Appeal Under License Agreement with Janssen Biotech, Inc

Pfizer Inc. and Genmab A/S Announce U.S. Food and Drug Administration Accepts TIVDAK® Supplemental Biologics License Application

Genmab A/S and AbbVie Announces New Pivotal Data for Bispecific Antibody Epcoritamab (Duobody CD3xCD20) Demonstrates High Overall and Complete Responses in Patients with Hard-To-Treat Relapsed/Refractory Follicular Lymphoma

Genmab A/S Announces Positive Regulatory Updates for Epcoritamab (EPKINLY®?/TEPKINLY®?) for the Treatment of Relapsed/Refractory Follicular Lymphoma

Genmab A/S Announces Positive Regulatory Updates for Epcoritamab (EPKINLY®?/TEPKINLY®?) for the Treatment of Relapsed/Refractory Follicular Lymphoma

Genmab A/S Revises Earnings Guidance for the Year 2023

Genmab A/S, Annual General Meeting, Mar 13, 2024

Genmab A/S to Report Q1, 2024 Results on May 02, 2024

Genmab A/S and Seagen Inc. Announce Additional Results from the Phase 3 innovaTV 301 Randomized Global Trial

Genmab A/S Announces European Commission Approval of Tepkinly(R) (epcoritamab) for Adults with Relapsed Or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Seagen Inc. and Genmab A/S Announce That Tivdak(R) (Tisotumab Vedotin-Tftv) Met Its Primary Endpoint of Improved Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared to Chemotherapy

Genmab A/S Revises Earning Guidance for the Year 2023

Genmab A/S Announces AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY(R) Diffuse Large B-Cell Lymphoma

AbbVie and Genmab Announce Positive Topline Results from Phase 1/2 EPCORE™ NHL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)

Genmab A/S Announces Epcoritamab Added to National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for ‘B-Cell Lymphomas’

Genmab A/S Showcases Data from Comprehensive Epcoritamab Development Program in Patients Across B-Cell Lymphomas At European Hematology Association (EHA) Annual Meeting 2023

U.S. Food and Drug Administration Approves Genmab A/S’s EPKINLY (epcoritamab-bysp) as the First and Only Bispecific Antibody to Treat Adults with Relapsed or Refractory Diffuse Large B-cell Lymphoma

Genmab A/S Provides Earnings Guidance for 2023

Genmab A/S Announces Submission of Japan New Drug Application for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma

Genmab A/S Showcases Data From Robust Development Program Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients Across a Broad Range of B-Cell Lymphomas at the 64th Annual ASH Meeting

Genmab A/S to Report Nine Months, 2023 Results on Nov 07, 2023

Genmab A/S Announces U.S. Food and Drug Administration Accepts for Priority Review Biologics License Application (Bla) for Epcoritamab (Duobody®-Cd3xcd20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (Lbcl)

Genmab Provides Earnings Guidance for Year 2022

Genmab A/S Submits Biologics License Application to the U.S. Food and Drug Administration

Genmab A/S Revises Earnings Guidance for the Year 2022

Genmab A/S Submits Biologics License Application to U.S. Food and Drug Administration for Epcoritamab for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma

Genmab Announces Late-Breaking Phase 2 Trial Results of Investigational Epcoritamab (DuoBody®-CD3xCD20) in Relapsed/Refractory Large B-cell Lymphoma (LBCL) Patients Presented at European Hematology Association (EHA) Presidential Symposium

Genmab A/S and Seagen Inc. Present Data from Tisotumab Vedotin (TIVDAK) Clinical Development Program and Additional Cervical Cancer Research at ASCO 2022 Annual Meeting

Genmab A/S Revises Earnings Guidance for 2022

AbbVie and Genmab Announce Topline Results for Epcoritamab (DuoBody®-CD3xCD20) from Phase 1/2 Trial in Patients with Relapsed/Refractory Large B-cell Lymphoma (LBCL)

Genmab A/S Elects Elizabeth O’Farrell to the Board of Directors

Genmab A/S Announces Appointments of Birgitte Stephensen to Chief Legal Officer and Chris Cozic to Chief People Officer

Genmab A/S Provides Earnings Guidance for the Year 2022

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Genmab A/S Announces Janssen Received Conditional European Marketing Authorization for RYBREVANT

High number of new directors

Analyse de la rémunération des PDG

PDG

Titularisation

Compensation

Équipe de direction

Durée moyenne de l'emploi

Âge moyen

Membres du conseil d'administration

Durée moyenne de l'emploi

Âge moyen